Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription 03.08.2026 1 Am J Respir Crit Care Med 2 Ann Surg Oncol 1 Ann Thorac Surg 6 Anticancer Res 1 Br J Cancer 1 Cancer Chemother Pharmacol 1 Cancer Lett 1 Cancer Res 2 Cancer Sci 4 Chest 2 Clin Cancer Res 2 Clin Exp Metastasis 3 Clin Lung Cancer 1 Eur J Cancer 2 Int J Cancer 2 Int J Radiat Oncol Biol Phys 1 J Cancer Res Clin Oncol 2 J Clin Oncol 2 J Nucl Med 2 J Thorac Cardiovasc Surg 2 J Thorac Oncol 4 Lung Cancer 1 Oncogene 4 PLoS One 1 Science

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Respir Crit Care Med

1. SCHWARTZ J, Murn M, Laniado I, Studts JL, et al
   Tool In Lesion- But Still Off Target: A Call of Concern for Lung Cancer Screening.
   Am J Respir Crit Care Med. 2026 Jul 27:aamag393. doi: 10.1093.
   PubMed        
   
   

   
   Ann Surg Oncol

2. TANG WF, Huang SQ, Li HJ, Tang X, et al
   ASO Visual Abstract: Pathologic Response, Tumor Microenvironment Dynamics, and Survival Dissociation After Neoadjuvant Chemoimmunotherapy for Lung Cancer With Rare Histologic Subtypes.
   Ann Surg Oncol. 2026 Jul 31. doi: 10.1245/s10434-026-20163.
   PubMed        
   
   
3. HERRERA LJ, Wright GM, Kim JY, Reisenauer JS, et al
   Phase II Multicenter Clinical Trial of Intraoperative Molecular Imaging with Abenacianine During Lung Cancer Surgery.
   Ann Surg Oncol. 2026 Jul 26. doi: 10.1245/s10434-026-19951.
   PubMed         Abstract available
   
   

   
   Ann Thorac Surg

4. BROAD SR, Wei J, Denson K, Shi Z, et al
   Association Between Rare Germline Variants in Cancer Susceptibility Genes and Lung Cancer Risk.
   Ann Thorac Surg. 2026 Jul 31:S0003-4975(26)00752.
   PubMed         Abstract available
   
   

   
   Anticancer Res

5. SHEN TC, Yang YC, Li CH, Tsai CW, et al
   Significant Association of Cyclin Dependent Kinase Inhibitor 1B Genotypes With Lung Cancer Risk Among Smokers.
   Anticancer Res. 2026;46:4311-4321.
   PubMed         Abstract available
   
   
6. ISHIKAWA Y, Woo T, Adachi H, Isaka T, et al
   Impact of Postoperative Complications on Long-term Survival in Patients With Non-small Cell Lung Cancer.
   Anticancer Res. 2026;46:4479-4488.
   PubMed         Abstract available
   
   
7. MOCHIDA K, Miyasaka Y, Kubo N, Yoshida H, et al
   Local Recurrence Prediction After Carbon-ion Radiotherapy for Early-stage Non-small Cell Lung Cancer Using Machine Learning.
   Anticancer Res. 2026;46:4431-4441.
   PubMed         Abstract available
   
   
8. HWANG HH, Cho SG
   Kisspeptin Signaling Suppresses HRas(G12V)-induced Tumor Growth and Metastasis by Inhibiting SP1-dependent N-cadherin Expression in NIH3T3 Cells.
   Anticancer Res. 2026;46:4331-4343.
   PubMed         Abstract available
   
   
9. MANIWA H, Ohno S
   Effects of Rehabilitation Before and After Pulmonary Resection: A Literature Review.
   Anticancer Res. 2026;46:4619-4626.
   PubMed         Abstract available
   
   
10. TATSUMI S, Nishikawa T, Hirata CL, Sawabata N, et al
    Stable Wet-Fixed S-MPF Preparation for Enhanced Circulating Tumor-associated Cell (C-TAC) Analysis.
    Anticancer Res. 2026;46:4291-4300.
    PubMed         Abstract available
    
    

    
    Br J Cancer

11. SUN M, Zang D, Chen J
    Clarifying causal and translational inference in studies of ambient PM2.5 and lung cancer.
    Br J Cancer. 2026 Jul 27. doi: 10.1038/s41416-026-03555.
    PubMed        
    
    

    
    Cancer Chemother Pharmacol

12. MAKINO Y, Ogawa T, Makihara-Ando R, Sakiyama N, et al
    Development of a simplified population pharmacokinetic-pharmacodynamic framework for exposure-informed risk stratification of neutropenia during amrubicin treatment.
    Cancer Chemother Pharmacol. 2026;96:81.
    PubMed         Abstract available
    
    

    
    Cancer Lett

13. CHE Z, Zeng C, Jiang D, Wang W, et al
    Blocking pyruvate carboxylase expression triggers ferroptosis and inhibits non-small cell lung cancer progression.
    Cancer Lett. 2026 Jul 27:218764. doi: 10.1016/j.canlet.2026.218764.
    PubMed         Abstract available
    
    

    
    Cancer Res

14. GHAEMI B, Olkowski CP, Basuli F, Shi J, et al
    SEZ6-Targeted PET Imaging and Alpha-Particle Radioimmunotherapy is Effective for Detection and Treatment of Small Cell Lung Cancer.
    Cancer Res. 2026 Jul 29. doi: 10.1158/0008-5472.CAN-25-5938.
    PubMed         Abstract available
    
    

    
    Cancer Sci

15. CHENG N, Jiang R, Li W, Huang W, et al
    Feiwei Heji Enhances Antitumor Immunity by MLL4-Dependent Regulation of Pyroptosis in Lung Cancer.
    Cancer Sci. 2026 Jul 31. doi: 10.1111/cas.70459.
    PubMed         Abstract available
    
    
16. TSURUMI K, Nomura M, Ouchi M, Yagishita S, et al
    Nicotinic Acid Restriction Enhances the Therapeutic Benefit of NAMPT Inhibition in Small-Cell Lung Cancer Models.
    Cancer Sci. 2026 Jul 28:10.1111/cas.70486. doi: 10.1111/cas.70486.
    PubMed         Abstract available
    
    

    
    Chest

17. KANG D, Yoo JW, Lee M, Ryu DH, et al
    Reduced Risk of Lung Cancer Associated with Sodium-Glucose Cotransporter-2 Inhibitors in Patients with COPD and Type 2 Diabetes Mellitus.
    Chest. 2026 Jul 27:S0012-3692(26)06297-5. doi: 10.1016/j.chest.2026.07.5208.
    PubMed         Abstract available
    
    
18. QIN J, Sun M, Li X, Duan X, et al
    Development and Multi-center Validation of a Breathomics-Based Triage Tool for Lung Cancer: A Prospective Study of 5,214 Participants.
    Chest. 2026 Jul 28:S0012-3692(26)06310-5. doi: 10.1016/j.chest.2026.
    PubMed         Abstract available
    
    
19. SUGUNESS A, Riley N, Kourouni I, Markovic M, et al
    The Impact of EHR Alerts to Correct Smoking History on Lung Cancer Screening: A Randomized Controlled Quality Improvement Initiative.
    Chest. 2026 Jul 29:S0012-3692(26)06315-4. doi: 10.1016/j.chest.2026.07.5218.
    PubMed        
    
    
20. SEEGER RP, Barr J, Sundaresan S, Lamb S, et al
    Lung Cancer's Social Identity: Historical Insights to Improve Collaborative Decision-Making for Surgery.
    Chest. 2026 Jul 31:S0012-3692(26)06321-X. doi: 10.1016/j.chest.2026.07.5223.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

21. HORIIKE A, Wakui H, Sugawara S, Minegishi Y, et al
    Efficacy and safety of necitumumab and pembrolizumab combination therapy in advanced non-small-cell lung cancer with >/=50% PD-L1 expression: A nonrandomized phase II trial.
    Clin Cancer Res. 2026 Jul 27. doi: 10.1158/1078-0432.CCR-25-2751.
    PubMed         Abstract available
    
    
22. VOKES NI, Symons JL, Rhead B, Hong L, et al
    The genomic landscape and treatment outcomes associated with CDKN2A/MTAP loss in patients with non-small cell lung cancer.
    Clin Cancer Res. 2026 Jul 27. doi: 10.1158/1078-0432.CCR-26-0771.
    PubMed         Abstract available
    
    

    
    Clin Exp Metastasis

23. CHEN H, Meng X, Cai L, Lei W, et al
    Treatment patterns and outcomes of second/third-line therapy in advanced non-small cell lung cancer with actionable genomic alterations (RECAP).
    Clin Exp Metastasis. 2026;43:38.
    PubMed         Abstract available
    
    
24. WANG S, Liu Y, Yu Y, Ren S, et al
    CYP4B1 inhibits lung adenocarcinoma metastasis by downregulating slug transcription via Sp1.
    Clin Exp Metastasis. 2026;43:37.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

25. GANTI AK, Damman B, Wang X, Stinchcombe TE, et al
    Outcomes Based on Age in CALGB 140503 (Alliance): Lobar Versus Sublobar Resection for Peripheral Stage IA Non-small Cell Lung Cancer.
    Clin Lung Cancer. 2026;27:42-49.
    PubMed         Abstract available
    
    
26. GOUTAM S, Gibson AJW, Dean ML, Miller AR, et al
    An Observational Population Level Study of Neoadjuvant Chemoimmunotherapy for Resectable Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2026;27:56-60.
    PubMed         Abstract available
    
    
27. GUIDRY JT, Carbone DP, Johnson ML, McKelvey BA, et al
    Streamlining the Frequency, Conduct, and Location of Assessments in Registrational Lung Cancer Clinical Trials for Supplemental Applications: Recommendations of a LUNGevity Foundation Multistakeholder Working Group.
    Clin Lung Cancer. 2026;27:61-67.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

28. AUCLIN E, Roulleaux Dugage M, Gorria T, Laguna JC, et al
    Validation of the lung immune prognostic index in extensive-stage small cell lung cancer: Post hoc analysis of the caspian and IMpower133 phase 3 trials.
    Eur J Cancer. 2026;245:116955.
    PubMed         Abstract available
    
    

    
    Int J Cancer

29. DE NIJS K, Ten Haaf K, Moldovanu D, Hubert J, et al
    The Optimal Lung Cancer Ct Screening Strategy: A Cost-Effectiveness Study Incorporating Nelson Evidence, Evolving Cost of Treatment and Smoking Cessation Interventions.
    Int J Cancer. 2026 Jul 29. doi: 10.1002/ijc.70655.
    PubMed         Abstract available
    
    
30. LIU J, Schneider MA, Held J, Wrenger S, et al
    Clinical Relevance of BACH1 Expression in Non-Small Cell Lung Cancer.
    Int J Cancer. 2026 Jul 26. doi: 10.1002/ijc.70673.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

31. WILSON LJ, Castillo R, Castillo E, Jones B, et al
    Prospective Evaluation of Novel 4DCT-Ventilation Imaging for Preoperative Risk Assessment in Lung Cancer: Results of the LIME Trial.
    Int J Radiat Oncol Biol Phys. 2026 Jul 30:S0360-3016(26)04076.
    PubMed         Abstract available
    
    
32. LIM R, O'Connor CS, Pan J, Tang TT, et al
    Predicting end-of-treatment ventilation response to radiotherapy using early treatment ventilation for patients with lung cancer treated with photons and protons.
    Int J Radiat Oncol Biol Phys. 2026 Jul 28:S0360-3016(26)04068.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

33. QIN L, Wang S, Qin H
    Interpreting the apparent benefit of thoracic radiotherapy in metastatic NSCLC: patient selection and analytical issues remain important-a comment on Xue et al.
    J Cancer Res Clin Oncol. 2026;152:150.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

34. LU C, Peng YL, Yang MY, Zhou Q, et al
    Anti-TIGIT in PD-L1-High Advanced Non-Small Cell Lung Cancer: Insights From SKYSCRAPER-01 and the Path Forward.
    J Clin Oncol. 2026 Jul 27:JCO2600935. doi: 10.1200/JCO-26-00935.
    PubMed        
    
    
35. PETERS S, Herbst R, Horinouchi H, Paz-Ares L, et al
    SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer.
    J Clin Oncol. 2026 Jul 27:JCO2502777. doi: 10.1200/JCO-25-02777.
    PubMed         Abstract available
    
    

    
    J Nucl Med

36. ALPER E, Ibrahim EA
    Concerns Regarding Brain [(18)F]FDG SUV(mean) as a Prognostic Biomarker in Advanced Non-Small Cell Lung Cancer.
    J Nucl Med. 2026 Jul 30:jnumed.126.272807. doi: 10.2967/jnumed.126.272807.
    PubMed        
    
    
37. AURIAC J, Buvat I, Orlhac F
    Reply: Concerns Regarding Brain [(18)F]FDG SUV(mean) as a Prognostic Biomarker in Advanced Non-Small Cell Lung Cancer.
    J Nucl Med. 2026 Jul 30:jnumed.126.273361. doi: 10.2967/jnumed.126.273361.
    PubMed        
    
    

    
    J Thorac Cardiovasc Surg

38. LULA LJ, Costa R, Franssen AJPM, Huang L, et al
    European analysis of patients with early-stage lung adenocarcinoma and invasive pathologic features who underwent lobectomy versus segmentectomy.
    J Thorac Cardiovasc Surg. 2026;172:413-421.
    PubMed         Abstract available
    
    
39. WOLF AS, Gulati S, Dolasia K, Fitzgerald B, et al
    Phase 1/1b study of direct intratumoral injection of pleural mesothelioma of immunostimulant prior to surgical resection.
    J Thorac Cardiovasc Surg. 2026;172:467-475.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

40. MOVSAS B, Hu C, Higgins KA, Ross HJ, et al
    Comprehensive Patient Reported Outcomes (PROs) from NRG Oncology/Alliance LU005: A Randomized Trial Of Chemoradiation +/- Atezolizumab In Limited-Stage Small Cell Lung Cancer.
    J Thorac Oncol. 2026 Jul 30:104117. doi: 10.1016/j.jtho.2026.104117.
    PubMed         Abstract available
    
    
41. TORASAWA M, Masui Y, Miura K, Kataoka S, et al
    Disease Kinetics and Practice Patterns in >/=4-Year Long-Term Beneficiaries of Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer.
    J Thorac Oncol. 2026 Jul 28:104113. doi: 10.1016/j.jtho.2026.104113.
    PubMed         Abstract available
    
    

    
    Lung Cancer

42. NAGASAKA M, Liu G, Perol M, Chen W, et al
    Comparative efficacy of taletrectinib versus first-generation TKIs in TKI-naive ROS1+ non-small cell lung cancer: A matching-adjusted indirect comparison.
    Lung Cancer. 2026;219:109538.
    PubMed         Abstract available
    
    
43. ZHOU X, Feng Y, Liang J, Bi X, et al
    Efficacy and safety of immune checkpoint inhibitors in lung cancer patients with hepatitis B surface antigen positivity: a real-world cohort study.
    Lung Cancer. 2026;219:109554.
    PubMed         Abstract available
    
    
44. BRONTE G
    Time-dependent bias in local consolidative therapy for EGFR-mutant metastatic non-small cell lung cancer.
    Lung Cancer. 2026;219:109550.
    PubMed        
    
    
45. VAN DER WEIJST L, Pompili C, Teixeira M, Hamzeh H, et al
    Evaluating health-related quality of life questionnaires in capturing common symptomatic adverse events in non-small cell lung cancer.
    Lung Cancer. 2026;219:109552.
    PubMed         Abstract available
    
    

    
    Oncogene

46. YIN D, Zhang C, Li Y, Dai J, et al
    The phase separation of ZC3H18 transcriptionally activates LDHA and forms lactylation-mediated positive feedback loop to promote tumorigenesis of lung cancer.
    Oncogene. 2026 Jul 26. doi: 10.1038/s41388-026-03817.
    PubMed         Abstract available
    
    

    
    PLoS One

47. LI R, Li B, Wang P
    Verbascoside triggers apoptosis and ferroptosis in NSCLC by targeting BCAT2.
    PLoS One. 2026;21:e0354955.
    PubMed         Abstract available
    
    
48. KHADKA S, Thornton JD, Kamal KM, Higa G, et al
    Pattern of opioid prescriptions among patients with breast, lung, and colorectal cancer diagnosed with pre-existing chronic non-cancer pain.
    PLoS One. 2026;21:e0352907.
    PubMed         Abstract available
    
    
49. HANNA NM, Shakeel S, Akhtar-Danesh GG, Akhtar-Danesh N, et al
    Factors affecting lung cancer stage at diagnosis and receipt of surgery in Ontario: A population-based analysis.
    PLoS One. 2026;21:e0354330.
    PubMed         Abstract available
    
    
50. FUCHS P, Reumueller A, Kreminger J, Zafeiri E, et al
    Choroidal metastasis: Impact of primary tumors and age on survival - a single center analysis.
    PLoS One. 2026;21:e0354598.
    PubMed         Abstract available
    
    

    
    Science

51. SUN Y, Zhong Y, Liu S, Zhang Z, et al
    Spatiotemporal multiomics uncover tumor ecosystem dynamics during metastatic colonization.
    Science. 2026;393:eadz7928.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum